Viferon, rectal suppositories 3 000 000me, 10pcs

Composition

1 suppository VIFERON® 3000000 IU contains the Active ingredient:

human recombinant Interferon alfa-2b 3000000 IU,

excipients:

ascorbic acid 0.0081 g,

sodium ascorbate 0.0162 g,

alpha-tocopherol acetate 0.055 g,

disodium edetate dihydrate 0.0001 g,

polysorbate-80 0.0001 g,

cocoa butter 0.1941 g,

confectionery fat or cocoa butter substitute up to 1 g

Pharmacological action

Human recombinant Interferon alfa-2b has antiviral, immunomodulatory, and antiproliferative properties, and suppresses the replication of RNA and DNA – containing viruses. The immunomodulatory properties of Interferon alfa-2b, such as an increase in the phagocytic activity of macrophages, an increase in the specific cytotoxicity of lymphocytes to target cells, determine its indirect antibacterial activity.

In the presence of ascorbic acid and alpha-tocopherol acetate, the specific antiviral activity of Interferon alfa-2b increases, its immunomodulatory effect increases, which makes it possible to increase the effectiveness of the body’s own immune response to pathogenic microorganisms.

When using the drug, the level of secretory class A immunoglobulins increases, the level of immunoglobulin E normalizes, and the endogenous Interferon alfa-2b system is restored. Ascorbic acid and alpha-tocopherol acetate, being highly active antioxidants, have anti-inflammatory, membrane-stabilizing, and regenerating properties.

It was found that when using the drug VIFERON®, there are no side effects that occur with parenteral use of Interferon alfa-2b preparations, antibodies that neutralize the antiviral activity of Interferon alfa-2b are not formed. The use of VIFERON® as part of complex therapy can reduce the therapeutic doses of antibacterial and hormonal drugs, as well as reduce the toxic effects of this therapy.

Cocoa butter contains phospholipids that prevent the use of synthetic toxic emulsifiers in production, and the presence of polyunsaturated fatty acids facilitates the introduction and dissolution of the drug.

Indications

— acute respiratory viral infections, including influenza, including bacterial infection, pneumonia (bacterial, viral, chlamydial) in children and adults as part of complex therapy;

infectious-inflammatory diseases of newborns, including preterm: meningitis (bacterial, viral), sepsis, intrauterine infection (chlamydia, herpes, cytomegalovirus infection, enterovirus infection, candidiasis, including visceral, mycoplasmosis) as part of complex therapy;

chronic viral hepatitis b, C, D in children and adults in the complex therapy, including in combination with the use of plasmapheresis and hemosorption in chronic viral hepatitis pronounced activity, complicated by cirrhosis of the liver;

infectious-inflammatory diseases of the urogenital tract (chlamydia, cytomegalovirus infection, ureaplasmosis, trichomoniasis, gardnerellosis, human papillomavirus infection, bacterial vaginosis, recurrent vaginal candidiasis, mycoplasmosis) in adults in the complex therapy;

primary or recurrent herpes infection of the skin and mucous membranes, localized form, light, and moderate flow, including the urogenital form in adults.

Use during pregnancy and lactation

Viferon is approved for use from the 14th week of pregnancy.

It has no restrictions for use during lactation.

Contraindications

Hypersensitivity to the drug’s components.

Side effects

In rare cases, allergic reactions (skin rashes, itching) may develop.

These phenomena are reversible and disappear 72 hours after discontinuation of the drug.

How to take, course of use and dosage

The drug is used rectally. 1 suppository contains human recombinant Interferon alfa-2b as the Active ingredient in the indicated dosages (150,000 IU,500,000 IU,1,000,000 IU,3,000,000 IU).

Acute respiratory viral infections, including influenza, including those complicated by bacterial infection, pneumonia (bacterial, viral, chlamydial) in children and adults as part of complex therapy.

Recommended dose for adults, including pregnant women and children over 7 years of age VIFERON® 500000 IU 1 suppository 2 times a day after 12 hours daily for 5 days. If clinically indicated, therapy may be continued.

Children under 7 years of age, including newborns and premature children with a gestational age of more than 34 weeks, are recommended to use the drug

VIFERON ® 150,000 IU 1 suppository 2 times a day after 12 hours daily for 5 days. If clinically indicated, therapy may be continued. The break between courses is 5 days.

Premature newborns with a gestational age of less than 34 weeks are recommended to use VIFERON ® 150,000 IU

1 suppository 3 times a day after 8 hours daily for 5 days.

If clinically indicated, therapy may be continued. The break between courses is 5 days.

Infectious and inflammatory diseases of newborns, including premature infants: meningitis (bacterial, viral), sepsis, intrauterine infection (chlamydia, herpes, cytomegalovirus infection, enterovirus infection, candidiasis, including visceral, mycoplasmosis) as part of complex therapy.

The recommended dose for newborns, including preterm children with a gestational age of more than 34 weeks, is VIFERON ® 150,000 IU daily,1 suppository 2 times a day after 12 hours. The course of treatment is 5 days.

Premature newborns with a gestational age of less than 34 weeks are recommended to use VIFERON ® 150,000 IU daily for 1 suppository 3 times a day after 8 hours. The course of treatment is 5 days.

Recommended number of courses for various infectious and inflammatory diseases: sepsis-2-3 courses, meningitis-1-2 courses, herpetic infection-2 courses, enterovirus infection-1-2 courses, cytomegalovirus infection – 2-3 courses, mycoplasmosis, candidiasis, including visceral-2-3 courses. The break between courses is 5 days. If clinically indicated, therapy may be continued.

Chronic viral hepatitis B, C, D in children and adults as part of complex therapy, including in combination with the use of plasmapheresis and hemosorption in chronic viral hepatitis of pronounced activity, complicated by cirrhosis of the liver.

The recommended dose for adults is VIFERON® 3000000 IU for 1 suppository 2 times a day after 12 hours daily for 10 days, then three times a week every other day for 6-12 months. The duration of treatment is determined by clinical efficacy and laboratory parameters.

Children under 6 months of age are recommended 300,000-500,000 IU / day; those aged 6-12 months – 500,000 IU / day.

Children aged 1 to 7 years are recommended to use 3000000 IU per 1 m2 of body surface area per day.

Children over 7 years of age are recommended 5000000 IU per 1 m2 of body surface area per day.

The drug is used 2 times a day after 12 hours for the first 10 days daily, then three times a week every other day for 6-12 months. The duration of treatment is determined by clinical efficacy and laboratory parameters.

The daily dose of the drug for each patient is calculated by multiplying the recommended dose for a given age by the body surface area calculated from the nomogram for calculating the body surface area in height and weight according to Garford, Terry and Rourke. Calculation of a single dose is carried out by dividing the calculated daily dose by 2 injections, the resulting value is rounded up to the dosage of the suppository.

In case of chronic viral hepatitis of pronounced activity and cirrhosis of the liver, before plasmapheresis and / or hemosorption, it is recommended to use VIFERON® 150,000 IU for children under the age of 7 years, and VIFERON® 500,000 IU for children over the age of 7 years,1 suppository 2 times a day after 12 hours daily for 14 days.

Infectious and inflammatory diseases of the urogenital tract (chlamydia, cytomegalovirus infection, ureaplasmosis, trichomoniasis, gardnerellosis, papillomavirus infection, bacterial vaginosis, recurrent vaginal candidiasis, mycoplasmosis) in adults, including pregnant women as part of complex therapy.

The recommended dose for adults is VIFERON® 500000 IU 1 suppository 2 times a day after 12 hours daily for 5-10 days. If clinically indicated, therapy may be continued.

Pregnant women from the second trimester of pregnancy (from 14 weeks of gestation) recommended the use of the drug VIFERON® 500,000 IU 1 suppository

2 times a day after 12 h daily for 10 days, then for 9 days 3 times with an interval of 3 days (the fourth day) 1 suppository 2 times a day after 12 hours. Further, every 4 weeks before delivery, VIFERON® 150,000 IU

1 suppository 2 times a day after 12 hours daily for 5 days.

If necessary, it is indicated before delivery (from the 38th week of gestation) to use the drug VIFERON® 500000 IU for 1 suppository 2 times a day after 12 hours daily for 10 days.

Primary or recurrent herpetic infection of the skin and mucous membranes, localized form, mild to moderate course, including urogenital form in adults, including pregnant women.

The recommended dose for adults is VIFERON ® 1000000 IU 1 suppository 2 times a day after 12 hours daily for 10 days or more in case of recurrent infection.If clinically indicated, therapy may be continued. It is recommended to start treatment immediately when the first signs of skin and mucous membrane lesions (itching, burning, redness) appear.

When treating recurrent herpes, it is advisable to start treatment in the prodromal period or at the very beginning of the manifestation of signs of relapse.

Pregnant women from the second trimester of pregnancy (from 14 weeks of gestation) recommended the use of the drug VIFERON® 500,000 IU 1 suppository

2 times a day after 12 h daily for 10 days, then for 9 days 3 times with an interval of 3 days (the fourth day) 1 suppository 2 times a day after 12 hours. Further, every 4 weeks before delivery, VIFERON® 150,000 IU 1 suppository 2 times a day after 12 hours daily for 5 days. If necessary, it is indicated before delivery (from the 38th week of gestation) to use the drug VIFERON® 500000 IU for 1 suppository 2 times a day after 12 hours daily for 10 days.

Special instructions

For the treatment of a wide range of infectious and inflammatory diseases, Viferon can be used in combination therapy with antibacterial drugs, glucocorticoids, and immunosuppressive drugs.

There are data on the effectiveness of using Viferon as part of complex therapy and for the prevention of the following diseases and conditions: herpetic infections, chlamydia, ureaplasmosis, toxoplasmosis, cytomegalovirus infection in adults and children older than 1 year; viral hepatitis in adults, acute respiratory viral infections, influenza, bronchial asthma, juvenile rheumatoid arthritis; meningeal form of tick-borne encephalitis; prostatitis of various etiologies; purulent septic postoperative complications, virus-associated glomerulonephritis, pyelonephritis.

Form of production

Rectal suppositories

Storage conditions

Store in a dry place, protected from light, at a temperature of 2-8 °C

Shelf life

2 years

Active ingredient

Interferon alfa-2b

Dosage form

rectal suppositories

Purpose

For adults as directed by your doctor

Indications

Hepatitis, Cirrhosis of the liver, Chlamydia, Urinary Tract infections, Trichomoniasis, Cytomegalovirus infection